Copper is an essential nutrient that is required for many vitally important processes, such as respiration, connective tissue biogenesis and iron metabolism. However, excess of copper represents a serious danger, due to its ability to induce free radical-induced oxidative damage, as well as impairments of lipid metabolism and neuronal activity. Wilson disease (WD) represents an excellent system for Cu toxicity studies. WD is caused by mutations in ATP7B pump effluxing excess Cu from hepatocytes into the bile. Loss of ATP7B leads to toxic Cu overload in liver and then in brain, causing fatal hepatic and neurologic abnormalities. Over the last years, C. elegans has emerged as an easy-to-use and highly responsive model of micronutrient metabolism. For this reason, we have generated and characterized a new C. elegans model of WD. CUA-1, the C. elegans ortholog of ATP7B, resides in lysosome-like organelles to sequester excess of copper and, therefore, represents a key component regulating copper supply and detoxification in order to maintain copper homeostasis. Using Crispr-Cas9 technology a
cua-1(
knu781 [H828Q]) strain was generated, that carries a substitution in conserved histidine corresponding to the most common H1069Q variant of ATP7B causing WD in European and North American population. In order to understand the effect of H828Q mutation on C. elegans phenotype we employed several assays that allow life span, motility, egg laying, larval development and mitochondria damage to be evaluated. Moreover, we are studying the colocalization of the mutant CUA-1 protein with markers of different organelles, such as lysosome, Golgi and ER, as well as with the copper sensor CF4. Our studies established that in absence of copper,
cua-1(
knu781) does not show any significant phenotypic aberrations. However, mutant worms exhibited very poor resistance to copper compared to the control strain. This manifested in a strong decrease in number of eggs, a delay in the larval development, a shorter lifespan, impaired motility and mitochondrial damage. Taken together our finding suggest that
cua-1(
knu781) represents an excellent model for Cu toxicity studies in WD. We further plan to use this model for identification and validation of the new therapeutic targets for WD. Moreover,
cua-1(
knu781) will be used for evaluation of the FDA-approved drugs that emerged from a high throughput screening for compounds reducing Cu toxicity in WD.